- 专利标题： Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen
-
申请号： US15955542申请日： 2018-04-17
-
公开(公告)号： US10258618B2公开(公告)日： 2019-04-16
- 发明人: Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Darren J. Baker , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Jan M. A. van Deursen
- 申请人： Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research
- 申请人地址： US CA Brisbane US CA Novato US MN Rochester
- 专利权人： UNITY BIOTECHNOLOGY, INC.,BUCK INSTITUTE FOR RESEARCH AGING,MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
- 当前专利权人： UNITY BIOTECHNOLOGY, INC.,BUCK INSTITUTE FOR RESEARCH AGING,MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
- 当前专利权人地址： US CA Brisbane US CA Novato US MN Rochester
- 代理机构： Wilson Sonsini Goodrich Rosati
- 代理商 Michael Schiff
- 主分类号： A61K9/00
- IPC分类号： A61K9/00 ; A61K31/496 ; A61K31/5377 ; A61P11/00 ; A61K31/428 ; A61K31/495 ; A61K31/404 ; A61K31/4375 ; A61K45/06 ; A61K31/4178 ; A61K31/728 ; C12N5/00 ; A61K47/36
摘要：
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
公开/授权文献
信息查询
